MENU
TECH
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

TECH stock forecast, quote, news & analysis

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets... Show more

Industry: #Biotechnology
TECH
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement

Bio-Techne (TECH) Stock Analysis: Analyst Upgrades Signal Biotech Resilience

Key Takeaways

  • TECH consensus rating "Moderate Buy" from 13 analysts, average price target $70.58 (+15% upside).
     
  • Recent upgrades: TD Cowen Oct 14 ($65→$70 Strong Buy), Evercore ISI Oct 7 ($60→$72 Buy), RBC Sep 3 (Hold→Buy $73).
     
  • Fiscal 2025 revenue +5.23% to $1.22B; Q4 EPS beat $0.53 vs $0.50 expected.
     
  • No downgrades in last 90 days; 42% Strong Buy ratings reflect proteomics growth confidence.
     

Current Market Snapshot

Bio-Techne Corporation (TECH) has maintained steady positioning across recent trading sessions within the biotechnology research tools sector. Shares reflect balanced sentiment amid clinical and academic demand cycles for proteomics platforms. Recent weeks demonstrate resilience against biotech index volatility, supported by recurring consumables revenue and spatial biology adoption. Trading patterns underscore investor focus on diversified end-markets spanning pharma, diagnostics, and life sciences.

AI Trading Bot Spotlight: TECH - AI Trading Agent with Corridor TP/SL 2%, 60min

The TECH - AI Trading Agent with Corridor TP/SL 2%, 60min applies financial learning models (FLMs) to identify signals on 60-minute timeframes, suited to biotech earnings and milestone-driven volatility. The corridor strategy enforces +2% take-profit above entry alongside -2% stop-loss below, delivering consistent 2:1 risk-reward ratios. This systematic approach captures momentum from clinical updates and analyst actions while limiting downside exposure. Simulations confirm effectiveness in TECH's moderate volatility profile. Deploy via Tickeron's platform to evaluate performance for automated biotech exposure.

Recent Developments Driving TECH Price Action

Bio-Techne Corporation (TECH) experienced measured price consolidation over recent weeks, balancing solid quarterly execution against year-over-year earnings contraction. Fiscal 2025 revenue grew 5.23% to $1.22 billion from $1.16 billion, propelled by Protein Sciences expansion and spatial biology platform traction. Net earnings declined 56.35% to $73.36 million due to R&D scaling and acquisition costs.

Q4 fiscal 2025 results on August 6 featured EPS of $0.53 beating $0.50 consensus, with revenue up 3.6% year-over-year to $316.96 million exceeding $315.14 million forecasts. Gross margins reached 46%, reflecting product mix optimization. Post-earnings shares appreciated initially, validating margin discipline amid Protein Sciences reagent demand and Diagnostics partnerships.

Analyst upgrades dominated recent coverage, driving positive sentiment shifts. TD Cowen maintained Strong Buy October 14, raising target $65 to $70. Evercore ISI held Buy October 7 ($60→$72). RBC Capital upgraded Hold to Buy September 3 ($61→$73). Earlier, Citigroup moved Hold to Strong Buy August 21 ($55→$70). Consensus "Moderate Buy" from 13 firms yields $70.58 average target (+15% upside); 42% Strong Buy ratings highlight proteomics leadership.

Macroeconomic factors influenced biotech peers more than TECH: inflation data and Fed signals prompted sector rotations, though TECH's 85%+ recurring revenue insulated performance. No negative catalysts emerged; XBI biotech index volatility created buying opportunities.

Price action showed volume spikes around earnings and upgrades, with shares digesting fiscal 2026 projections: 8.2% revenue growth to $1.25 billion, EPS $1.97 (+17.96%). Sentiment evolved toward valuation appeal at forward P/E aligned with peers, supported by clinical reagent pipeline.

Forward-Looking Factors to Watch

Monitor Q1 fiscal 2026 earnings in early January 2026, projecting $320 million revenue and $0.55 EPS. Fiscal 2026 consensus forecasts $1.25 billion revenue (+8.2%) and $1.97 EPS. Updates on spatial biology adoption, proteomics reagents, and Diagnostics milestones will clarify trajectory.

Analyst revisions continue tracking end-market diversification; full-year targets average $70.58. Product developments in high-throughput screening and next-gen sequencing represent catalysts amid NIH funding cycles.

Biotech sector monitors FDA approvals, M&A in research tools, and macro data like CPI/Fed commentary. Dividend and repurchase programs provide visibility per SEC filings.



 

A.I.Advisor
a Summary for TECH with price predictions
Jun 12, 2026

Momentum Indicator for TECH turns positive, indicating new upward trend

TECH saw its Momentum Indicator move above the 0 level on May 26, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned positive. In of the 89 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where TECH's RSI Oscillator exited the oversold zone, of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for TECH just turned positive on May 22, 2026. Looking at past instances where TECH's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

TECH moved above its 50-day moving average on June 08, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for TECH crossed bullishly above the 50-day moving average on June 12, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TECH advanced for three days, in of 303 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 13 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TECH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

TECH broke above its upper Bollinger Band on May 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for TECH entered a downward trend on May 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.055) is normal, around the industry mean (18.720). P/E Ratio (77.143) is within average values for comparable stocks, (36.072). Projected Growth (PEG Ratio) (0.744) is also within normal values, averaging (1.682). Dividend Yield (0.006) settles around the average of (0.038) among similar stocks. P/S Ratio (6.998) is also within normal values, averaging (357.550).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. TECH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TECH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
published Dividends

TECH paid dividends on May 29, 2026

Bio-Techne Corp TECH Stock Dividends
А dividend of $0.08 per share was paid with a record date of May 29, 2026, and an ex-dividend date of May 18, 2026. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Nektar Therapeutics (NASDAQ:NKTR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 1.9B. The market cap for tickers in the group ranges from 58 to 112.92B. VRTX holds the highest valuation in this group at 112.92B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 1%. For the same Industry, the average monthly price growth was 90%, and the average quarterly price growth was 2,051%. ELOX experienced the highest price growth at 118%, while ADTX experienced the biggest fall at -80%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 80%. For the same stocks of the Industry, the average monthly volume growth was 171% and the average quarterly volume growth was 155%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 81
Price Growth Rating: 59
SMR Rating: 94
Profit Risk Rating: 93
Seasonality Score: 12 (-100 ... +100)
View a ticker or compare two or three
TECH
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a biological products manufacturer

Industry Biotechnology

Profile
Details
Industry
Biotechnology
Address
614 McKinley Place N.E.
Phone
+1 612 379-8854
Employees
3050
Web
https://www.bio-techne.com
Bio-Techne (TECH) Stock Analysis: Analyst Upgrades Signal Biotech Resilience